Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 01 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 01 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.